Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children
Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children
复制标题
DOI：
10.1093/cid/ciw045
复制
发表时间：
2016-05-01
影响因子：
11.8
通讯作者：
Cortese, Margaret M.
中科院分区：
文献类型：
--
作者：
Sahakyan, Gayane;Grigoryan, Svetlana;Cortese, Margaret M.
背景亚美尼亚共和国是新独立国家中最早将轮状病毒疫苗纳入国家免疫规划以减少轮状病毒疾病负担的两个国家之一（记录显示，在5岁以下儿童中，38%的急性胃肠炎住院[AGE]）。在2012年11月，RV 1（Rotarix）引入亚美尼亚婴儿在6岁和12 week.Methods。a欧洲积分在首都埃里温的2家医院建立的主动监测系统，其中年龄< 5岁的儿童年龄住院年龄的轮状病毒抗原检测粪便样本，用于评估轮状病毒住院的趋势。从诊所获得疫苗引入后登记的儿童的免疫记录，并使用轮状病毒检测阴性的AGE儿童作为轮状病毒阳性病例的对照来估计疫苗有效性（VE）。在引进后的第2年和第3年，每千日元75%。在其他年龄太大而无法接种疫苗的幼儿中，每千日元减少30%，这表明间接保护带来了额外的好处;总体而言，在第3年，5岁以下儿童的轮状病毒住院率减少了69%。在6-23个月的儿童中，2剂RV 1预防轮状病毒住院（任何严重程度）的总体VE为62%（95%置信区间[CI]，36%-77%）; 6-11个月的儿童为68%（95% CI，24%-86%），12-23个月的儿童为60%（95% CI，20%-80%）。对更严重的轮状病毒病，VE是79%（95%CI，55%-90%），同样高，在两个年龄组。结论。aEuro积分RV 1是有效的年轻亚美尼亚儿童和大幅减少轮状病毒住院后不久推出。
Background. The Republic of Armenia was 1 of the 2 earliest countries in the Newly Independent States to introduce rotavirus vaccine into its national immunization program to reduce the burden of rotavirus disease (documented to cause 38% of acute gastroenteritis hospitalizations [AGE] among children aged < 5 years). In November 2012, RV1 (Rotarix) was introduced for Armenian infants at ages 6 and 12 weeks.Methods.aEuro integral The established active surveillance system at 2 hospitals in the capital, Yerevan, whereby children aged < 5 years hospitalized for AGE have stool sample tested for rotavirus antigen, was used to assess trends in rotavirus hospitalizations. Immunization records on children enrolled after vaccine introduction were obtained from clinics, and vaccine effectiveness (VE) was estimated using children with AGE who test negative for rotavirus as controls for the rotavirus-positive cases.Results.aEuro integral Among infants, rotavirus hospitalizations were reduced by 48% within the first year after introduction, and by a parts per thousand yen75% in years 2 and 3 following introduction. Reductions of a parts per thousand yen30% in other young children too old to have been vaccinated suggest additional benefit through indirect protection; overall in year 3, rotavirus hospitalizations were reduced by 69% among children aged < 5 years. The overall VE of 2 RV1 doses in protecting against rotavirus hospitalization (any severity) was 62% (95% confidence interval [CI], 36%-77%) among children aged 6-23 months; 68% (95% CI, 24%-86%) among those aged 6-11 months, and 60% (95% CI, 20%-80%) in children aged 12-23 months. Against more severe rotavirus disease, VE was 79% (95% CI, 55%-90%) and similarly high in both age groups.Conclusions.aEuro integral RV1 is effective in young Armenian children and substantially reduced rotavirus hospitalizations shortly after introduction.